PuSH - Publication Server of Helmholtz Zentrum München: Detection of early esophageal neoplastic barrett lesions with quantified fluorescence molecular endoscopy using Cetuximab-800CW.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Gabriels, R.Y.* ; van Heijst, L.E.* ; Hooghiemstra, W.T.R.* ; van der Waaij, A.M.* ; Kats-Ugurlu, G.* ; Karrenbeld, A.* ; Robinson, D.J.* ; Tenditnaya, A. ; Ntziachristos, V. ; Gorpas, D. ; Nagengast, W.B.*

Detection of early esophageal neoplastic barrett lesions with quantified fluorescence molecular endoscopy using Cetuximab-800CW.

J. Nucl. Med. 64, 803-808 (2023)

Publ. Version/Full Text

DOI

PMC

	Free by publisher

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Esophageal adenocarcinoma causes 6% of cancer-related deaths worldwide. Near-infrared fluorescence molecular endoscopy (NIR-FME) uses a tracer that targets overexpressed proteins. In this study, we aimed to investigate the feasibility of an epidermal growth factor receptor (EGFR)–targeted tracer, cetuximab-800CW, to improve detection of early-stage esophageal adenocarcinoma. Methods: We validated EGFR expression in 73 esophageal tissue sections. Subsequently, we topically administered cetuximab-800CW and performed high-definition white-light endoscopy (HD-WLE), narrow-band imaging, and NIR-FME in 15 patients with Barrett esophagus (BE). Intrinsic fluorescence values were quantified using multidiameter single-fiber reflectance and single-fiber fluorescence spectroscopy. Back-table imaging, histopathologic examination, and EGFR immunohistochemistry on biopsy samples collected during NIR-FME procedures were performed and compared with in vivo imaging results. Results: Immunohistochemical preanalysis showed high EGFR expression in 67% of dysplastic tissue sections. NIR-FME visualized all 12 HD-WLE–visible lesions and 5 HD-WLE–invisible dysplastic lesions, with increased fluorescence signal in visible dysplastic BE lesions compared with nondysplastic BE as shown by multidiameter single-fiber reflectance/single-fiber fluorescence, reflecting a target-to-background ratio of 1.5. Invisible dysplastic lesions also showed increased fluorescence, with a target-to-background ratio of 1.67. Immunohistochemistry analysis showed EGFR overexpression in 16 of 17 (94%) dysplastic BE lesions, which all showed fluorescence signal. Conclusion: This study has shown that NIR-FME using cetuximab-800CW can improve detection of dysplastic lesions missed by HD-WLE and narrow-band imaging.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Barrett Esophagus ; Cetuximab ; Epidermal Growth Factor Receptor ; Esophageal Adenocarcinoma ; Fluorescence Molecular Imaging; Adenocarcinoma

ISSN (print) / ISBN 0161-5505

e-ISSN 1535-5667

Journal Journal of Nuclear Medicine

Quellenangaben Volume: 64, Issue: 5, Pages: 803-808

Publisher Society of Nuclear Medicine and Molecular Imaging

Publishing Place 1850 Samuel Morse Dr, Reston, Va 20190-5316 Usa

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Biological and Medical Imaging (IBMI)

Grants H2020 Societal Challenges Programme
Bundesministerium fur Bildung und Forschung (BMBF) , Bonn, Germany
Dutch Cancer Society, Amsterdam, the Netherlands
European Union's Horizon 2020 research and innovation programme